NKGen Biotech to Showcase Troculeucel for Neurodegenerative Diseases at Guangzhou Forum — NKGen Biotech, Inc.

Event summary

NKGen Biotech CEO Paul Y. Song to present on troculeucel for neurodegenerative diseases at the 4th Great Bay Cell and Gene Therapy Forum on September 23, 2026.
Presentation will focus on troculeucel's mechanism of action, biomarker changes, and clinical experience in Alzheimer’s disease.
Troculeucel, an autologous NK cell therapy, is being developed for neurodegenerative disorders and various cancers.
The therapy has received International Nonproprietary Name (INN) approval from the World Health Organization.

The big picture

NKGen Biotech's presentation at the Great Bay Cell and Gene Therapy Forum underscores the growing interest in NK cell therapies for neurodegenerative diseases, a space traditionally dominated by small molecule and biologic approaches. The strategic focus on troculeucel aligns with broader industry trends toward personalized and cell-based treatments, particularly as the global burden of neurodegenerative diseases continues to rise. The WHO INN approval marks a critical milestone in NKGen's efforts to bring troculeucel to market, positioning the company within the competitive landscape of emerging cell therapies.

What we're watching

Clinical Validation: How initial clinical data on troculeucel in Alzheimer’s disease will influence its potential expansion into Parkinson’s disease and frontotemporal dementia.
Regulatory Progress: The pace at which NKGen Biotech advances troculeucel through regulatory pathways following the WHO INN approval.
Market Differentiation: Whether troculeucel can establish a competitive edge in the neurodegenerative disease space given the growing interest in cell-based therapies.